Filing Details
- Accession Number:
- 0001819790-21-000031
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-14 16:51:01
- Reporting Period:
- 2021-09-10
- Accepted Time:
- 2021-09-14 16:51:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1819790 | Tarsus Pharmaceuticals Inc. | TARS | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1788542 | Aziz Mottiwala | C/O Tarsus Pharmaceuticals, Inc. 15440 Laguna Canyon Road, Suite 160 Irvine CA 92618 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-09-10 | 4,350 | $10.99 | 58,203 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2021-09-10 | 2,593 | $0.45 | 60,796 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-09-10 | 2,593 | $22.15 | 58,203 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-09-10 | 4,350 | $10.99 | 4,350 | $10.99 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-09-10 | 2,593 | $0.45 | 2,593 | $0.45 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 14,989 | 2030-09-24 | No | 4 | M | Direct | |
| 772 | 2028-09-13 | No | 4 | M | Direct |
Footnotes
- The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $22.000 to $22.200. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Option granted under the Tarsus Pharmaceuticals, Inc. 2016 Stock Plan (the "Plan"). The option shares vest and become exercisable in 48 equal monthly installments beginning on October 25, 2020.
- Option granted under the Plan. 25% of the option shares vested and became exercisable on July 27, 2019 and the remaining option shares vest and become exercisable in 36 equal monthly installments thereafter.
Billionaire Hedge Funds
